Education
About Us
Working with TipRanks
Follow Us
Intensity Therapeutics, Inc. (INTS)
NASDAQ:INTS
Pazopanib, Int230-6, Eribulin, Trabectedin
Sarcoma,Soft Tissue
Phase III
Active Not Recruiting
A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)
Feb 01, 2024
―
Int230-6, Anti-Pd-1 Antibody, Anti-Ctla-4 Antibody
Breast Cancer, Lymphoma, Pancreatic Cancer, Sarcoma, Lung Cancer, Head And Neck Cancer, Bile Duct Cancer, Squamous Cell Carcinoma, Colon Cancer, Liver Cancer, Chordoma Of Sacrum
Phase I/II
Completed
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
Feb 10, 2017
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Intensity Therapeutics, Inc. (INTS) have in its pipeline
INTS is currently developing the following drugs: Pazopanib, Int230-6, Eribulin, Trabectedin, Int230-6, Anti-Pd-1 Antibody, Anti-Ctla-4 Antibody. These drug candidates are in various stages of clinical development as the company works toward FDA approval.